# A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.

> **NCT07229547** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Placebo
- **DRUG:** Onradivir tablet

## Key facts

- **NCT ID:** NCT07229547
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229547, "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07229547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*